Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.

ABSTRACT:

Background

The development and rapid uptake of immune checkpoint inhibitors (CPI) has changed the outlook for patients with cancer. However, CPIs have different adverse event (AE) profiles to other systemic therapies, and prompt AE management is essential to assure optimal outcomes. In order to understand what and when adverse events are experienced, reported and managed during CPI treatment, a mixed methods study was conducted, including a case note review of patients who were receiving immunotherapy and semi-structured interviews with patients to understand their experience, management and reporting of AEs after receiving immune CPI treatment.

Methods

This mixed methods study was conducted at a large cancer hospital in the United Kingdom. A case note review identified how

SUBMITTER: Jamieson L 

PROVIDER: S-EPMC7416581 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature